Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

DISRUPT On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology

Coordinator
Universitat Politecnica De Valencia, Spain
Runs
1 December 2022 to 31 May 2026
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
6 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101099663

What the project is doing

In the project's own words, from its summary on CORDIS.

DISRUPT aims at revolutionising the field of biomedical imaging by developing a radically new lab-a-on-chip technology: integrated tomographic microscopy. This unprecedented technique will be enabled by pushing forward the science of on-chip wireless photonics and tomography, in combination with microfluidics and artificial intelligence (AI). The CMOS compatibility of this technology represents a paradigm shift as it assures the realization of tomographic microscopes that are dramatically cheaper, lighter, and smaller than current approaches.

Moreover, the singular features of the proposed solution introduce key advantages in terms of resolution, sensitivity, throughput, parallelisation, and energy efficiency. To illustrate its potential, we will show that on-chip TPM can be used for cancer detection and the identification of infected cells. Developments related to fundamental nanoantenna and diffraction tomography science, nanophotonics, nanofabrication, microfluidics, AI and clinical validation will be undertaken by a consortium comprised by 2 SME, 1 HE, 1 Non-profit RO and 2 Cancer R&D Medical institutions, with complementary expertise, leaders in their respective markets and R&D fields.

This novel device is suited for many applications, such as early cancer diagnosis, cell characterisation, research on cancer and infectious diseases, immunocyte phenotyping, stem cell multipotency identification, tissue pathology, haematopathology, and analysis of infected cells. Its intrinsic mass-producible, compact, low-cost, mechanically robust, and energy-efficient feature makes this technology a future innovation driver for new developments in many biomedical application fields, and offers an alternative toolset addressing some of the emerging needs of microscopic analysis and diagnostics in low-resource settings, telemedicine applications and point-of-care, having a potentially huge societal impact fostering early diagnosis of cancer and other diseases and infections.

Topics

Who is involved

OrganisationCityCountryRole
Universitat Politecnica De ValenciaValenciaSpainCoordinator
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyParticipant
Microfluidic Chipshop GmbHJenaGermanyParticipant
Das Photonics SLValenciaSpainParticipant
Instituto Valenciano De OncologiaValenciaSpainParticipant
Fondazione Irccs Istituto Nazionale Dei TumoriMilanItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI